“Our focus is really on patients who’ve lost a lot of kidney function, 70 to 75% or even 80% of their kidney function,” says Bruce Culleton, CEO of ProKidney. “They’re on the path to needing a transplant. Despite all the advances in treating patients with newer products over the last few years, patients continue to progress. Our goal is to intervene directly before dialysis and keep patients off dialysis for as long as possible.” In this Vanguards of Healthcare podcast episode, Culleton sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk for an in-depth discussion about how the company’s cell therapy could help delay dialysis and slow the progression of kidney disease.

See omnystudio.com/listener for privacy information.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Bloomberg. Innehållet i podden är skapat av Bloomberg och inte av, eller tillsammans med, Poddtoppen.